Comparative Assessment of Liver Function During the Intensive Phase of Treatment of Respiratory Tuberculosis Patients Treated with First Line and Reserve Drugs
https://doi.org/10.21292/2075-1230-2021-99-7-41-47
Abstract
The objective: to compare liver function of respiratory tuberculosis patients during the intensive phase of treatment with first line drugs (chemotherapy regimen 1) and reserve drugs (chemotherapy regimens 4 and 5).
Subjects and Methods: Data of 144 respiratory tuberculosis patients were analyzed, those patients were divided into 2 groups. Group 1 included 67 patients receiving chemotherapy regimen 1 and Group 2 included 77 patients treated with chemotherapy regimens 4 or 5. During the first 3 months of treatment, the frequency and severity of changes in the liver function were assessed.
Conclusion: in patients with chronic viral hepatitis, parenchymal liver damage is more frequent and it improves slower. Transaminase levels returned to normal levels more frequently and rapidly with chemotherapy regimen 1, whereas with chemotherapy regimens 4 and 5, reduction of alanine aminotransferase level was observed only from the 2nd month of treatment.
About the Authors
E. V. Vаniev
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Eduard V. Vaniev – Candidate of Medical Sciences, Head of Therapy Department no. 2.
4, Dostoevsky St., Moscow, 127473
N. V. Kuzminа
Surgut State University
Russian Federation
Russian Federation
Natalya V. Kuzmina – Professor of Department for Multiple Discipline Clinical Training.
1, Lenina Ave., Surgut, KhMAO-Yugra, 628412
I. А. Vаsilyevа
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Irina A. Vasilyeva – Doctor of Medical Sciences, Professor, Director.
4, Dostoevsky St., Moscow, 127473
References
1. Аbdullaev R.Yu., Vaniev E.V., Kaminskaya G.O., Vasilyeva I.А., Komissarova O.G. Evaluation of functional liver state in patients suffering from new pulmonary tuberculosis when using I and IIB chemotherapy regimens. Probl. Tuberkuleza i Bolezni Legkikh, 2009, no. 2, pp. 57-61. (In Russ.).
2. Vaniev E.V. Effektivnost khimioterapii vpervye vuyavlennykh bolnykh destruktivnym tuberkulezom legkikh s lekarstvennoy ustoychivostyu MBT. Avtoref. diss. kand. med. nauk. [Chemotherapy efficacy of new destructive pulmonary tuberculosis patients with drug resistance. Synopsis of Cand. Diss.] Moscow, 2008, 26 p.
3. Eremina E.Yu. Drug-associated liver disorders. Praktich. Meditsina, 2014, no. 1, pp. 20-30. (In Russ.).
4. Harada Y., Kawakami K., Koyama K. et al. Case of fatal liver failure due anti-tuberculous therapy. Kekkaku, 2007, vol. 82, suppl. 9, pp. 705-709.
5. Javadi M.R., Shalviri G., Gholami K. et al. Adverse reactions of antituberculosis drugs in hospitalized patients: incidence, severity and risk factors. Pharmacoepidemiol. Drug Saf., 2007, vol. 16, suppl.10, pp. 1104-1110.
6. Santhosh S., Sini T. K., Anandan R. et al. Hepatoprotective activity of chitosan against isoniazid and rifampicin-induced toxicity in experimental rats. Eur. J. Pharmacol., 2007, vol. 572, suppl. 1, pp. 69-73.
7. Shigeto E. Committee for Treatment Japanese Society for Tuberculosis. Survey of anti-tuberculosis drug-induced severe liver injury in Japan. Kekkaku, 2007, vol. 82, suppl. 5). pp. 467-473.
8. Sotgiu G., Centis R., D’ambrosio Lia, Migliori G.B. Tuberculosis treatment and drug Regimens. Cold Spring Harb Perspect Med., 2015, vol. 5, pp. a017822.
9. Vilarica A., Pina J., Diogo N. et al. Adverse reactions from antituberculosis drags. Rev. Port. Pneumon., 2007, vol. 13, suppl. 6, pp. 21-22.
10. Wong W.M., Wu P.C., Yuen M.F., Cheng C.C., Yew W.W., Wong P.C., Tam C.M., Leung C.C., Lai C.L. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology, 2000, vol. 31, no. 1, pp. 201-206.
Review
For citations:
Vаniev E.V., Kuzminа N.V., Vаsilyevа I.А. Comparative Assessment of Liver Function During the Intensive Phase of Treatment of Respiratory Tuberculosis Patients Treated with First Line and Reserve Drugs. Tuberculosis and Lung Diseases. 2021;99(7):41-47. (In Russ.) https://doi.org/10.21292/2075-1230-2021-99-7-41-47
Views:
574
Email this article 